Morgan Stanley maintains BridgeBio Oncology at Overweight, lowers price target to $12 from $13
Morgan Stanley kept its Overweight rating on BridgeBio Oncology but reduced its price target to $12 from $13, a 7.7% decrease. The new target suggests a 518.6% upside from the Nov 17 close of $1.94. Recent analyst price targets for the company range from $9 to $16.

